Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adul
Go back to Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adul| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.11 -0.78 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.89 | 52 Week High | $108.63 | |||
| Open | $150.56 | 52 Week Low | $71.39 | |||
| Day High | $153.23 | P/E | 82.93 | |||
| Day Low | $149.57 | EPS | $1.81 | |||
| Volume | 16,453,710 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 146.87 -0.28 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.15 | 52 Week High | $65.46 | |||
| Open | $147.08 | 52 Week Low | $47.97 | |||
| Day High | $147.84 | P/E | 99.91 | |||
| Day Low | $145.74 | EPS | $1.47 | |||
| Volume | 31,159,364 | |||||
